Apellis’ EMPAVELI holds the distinction of being the first and only approved therapy for C3 glomerulopathy and IC-MPGN in patients aged 12 and older, adults and those with post-transplant recurrence. The U.S. patient population is estimated at roughly 5,000 individuals, with EMPAVELI enjoying exclusive approval for approximately two-thirds of that pool. In December 2025, the European CHMP issued a positive opinion, setting the stage for a broadened global launch. Rare-disease pricing typically yields gross margins above 90%, underscoring the franchise’s potential to drive high-margin revenue as geographic expansion unfolds.

Management targeted 225 cumulative patient start forms by the end of 2025 but recorded only 152 through September, implying the need to add 73 forms in Q4. That trajectory suggests a slowdown to roughly 24 patient starts per month if guidance is met, compared with an early-adopter wave that averaged 76 starts per month in July and August. CEO Cedric Francois characterized this pattern as a one-time surge followed by ‘‘steady, consistent growth’’ next year, indicating a measured ramp rather than a rapid inflection.

Syfovre generated $151 million in Q3 2025 U.S. sales, essentially flat versus Q2’s $161 million, with injection volume growth of just 4%—largely driven by $15 million of free product shipments. New‐patient share slipped to 52%, as many retina specialists adopted a cautious ‘‘wait-and-see’’ stance despite Syfovre’s 60% market share. Patient access challenges—exacerbated when a key co-pay assistance foundation ceased new applications—echo across the geographic atrophy segment, forcing peers to revise guidance and slowing new enrollments industry-wide.

Despite regulatory triumphs, the stock is down approximately 31% over the past year, signaling investor skepticism around commercial execution. At roughly 57x trailing earnings and 46x forward earnings, the market is pricing in an ambitious growth trajectory that current launch metrics do not yet support. A near-term catalyst could emerge from the European expansion and resolution of access issues over 12–18 months. However, management’s commitment to ‘‘steady, measured’’ growth rather than a steep acceleration suggests the story remains one of steady progress rather than a breakthrough moment.